Michael Kaplan

Davis Polk advised BiondVax Pharmaceuticals Ltd. in connection with its registered at-the-market offering of shares of its American depositary shares for up to a maximum offering price of …

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by Energizer Holdings, Inc. of $800 million aggregate principal…

Davis Polk advised the joint book-running managers in connection with an offering by Advance Auto Parts, Inc. of $350 million aggregate principal amount of its 1.750% notes due 2027…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by Hologic, Inc. of $950 million aggregate principal amount of its…

Davis Polk advised the representatives of the initial purchasers in a Rule 144A offering by Omnicell, Inc. of $575 million aggregate principal amount of 0.25% convertible senior notes due…

Davis Polk advised the representative of the underwriters in connection with an SEC-registered offering by YUM! Brands, Inc. of $1.05 billion aggregate principal amount of 3.625%…

Davis Polk advised American Well Corporation (“Amwell”) in connection with its initial public offering of 47,405,555 shares of Class A common stock for approximately $853 million in total…

Davis Polk advised the underwriter in connection with a $282 million public offering of 5,100,000 shares of Class A common stock of Chewy, Inc. In addition, the underwriter has an…

Davis Polk advised Max Stock Ltd., as the issuer and Moose Holdco Ltd., Uri Max Ltd. and Oria & Iris Ltd. LP, as the selling shareholders on Max Stock’s initial public offering and…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by Uber Technologies, Inc. of $500 million aggregate principal…